| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.02. | Actinogen Medical - XanaMIA Phase IIb/III study marches on | 279 | Edison Investment Research | Actinogen Medical continues to make progress with its 36-week XanaMIA Phase IIb/III study assessing Xanamem in patients with biomarker-positive mild-to-moderate Alzheimer's disease (AD). The company... ► Artikel lesen | |
| 13.02. | Mendus - Focus firmly on pivotal-stage readiness in 2025 | 283 | Edison Investment Research | Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE... ► Artikel lesen | |
| 13.02. | Cereno Scientific - CS014 achieves another Phase I milestone | 208 | Edison Investment Research | Cereno Scientific's second pipeline asset, CS014, continues to make steady progress through the clinic, with the company successfully completing the single ascending dose (SAD) part of the Phase I study... ► Artikel lesen | |
| 13.02. | Creo Medical - Consumables business divestment concludes | 232 | Edison Investment Research | Creo Medical has completed the sale of the majority (51%) stake in its European consumable business to Chinese medical device manufacturer Micro-Tech for net proceeds of c €30m (c £25m). The deal valued... ► Artikel lesen | |
| 13.02. | RELX (LSE: REL) - Good momentum into FY25 | 311 | Edison Investment Research | RELX has turned in a very good performance for 2024, with underlying revenue growth of 7% and a step-up in adjusted operating margin from 33.1% to 33.9%. Encouragingly, there was progress in margin... ► Artikel lesen | |
| 13.02. | British American Tobacco (LSE: BATS) - FY24 results in line | 664 | Edison Investment Research | British American Tobacco (BAT) navigated a year of transformation in 2024, with its pivot towards a smokeless future gaining momentum. The company added 3.6 million new adult users of its smokeless... ► Artikel lesen | |
| 13.02. | Immix Biopharma - NXC-201 receives FDA RMAT designation | 236 | Edison Investment Research | Immix Biopharma has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for the company's novel sterically optimized CAR-T treatment... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 2.593 |
| EVOTEC | 2.177 |
| NOVO NORDISK | 1.656 |
| RHEINMETALL | 1.087 |
| TESLA | 1.031 |
| RENK GROUP | 1.028 |
| BYD | 828 |
| TUI | 810 |
| DEUTZ | 794 |
| STEYR MOTORS | 785 |
| SIEMENS ENERGY | 692 |
| UNITEDHEALTH | 620 |
| PLUG POWER | 583 |
| NEL | 566 |
| APPLE | 505 |
| VOLKSWAGEN | 483 |
| PUMA | 482 |
| BASF | 447 |
| ALMONTY | 439 |
| ELI LILLY | 424 |
| DEUTSCHE BANK | 422 |
| BAYER | 420 |
| MERCEDES-BENZ | 401 |
| TSMC | 396 |
| XIAOMI | 384 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
